To evaluate the budget impact on the Italian NHS of rosiglitazone based treatment strategies, compared to current therapy. METHODS: Estimated target population for alternative treatments was based on algorithms previously reported*. Three groups of patients were identified to compare alternative treatment strategies: 1) Rosiglitazone monotherapy vs. SU monotherapy; 2) Rosiglitazone + metformin vs. SU + metformin; and 3) Siglitazone + SU vs. insulin alone or in association with SU. The perspective used was that of the Italian NHS. Time horizon was one year. Costs/patient/year considered were: drug acquisition costs; glycaemia self-monitoring costs; severe hypoglycaemias costs; and clinical tests costs (according to therapy). Glycaemia self-monitoring assumptions were based on AMD (Italian Association of Diabetologists) guidelines. Sensitivity analysis was performed to test the robustness of the assumptions made and their influence on the results. RESULTS: The epidemiological algorithms assigned 19.84% of patients to group 1, 37.8% to group 2 and 42.36% to group 3. Treatment costs/patient/year were: group 1-€459,91 for rosiglitazone vs. €469,06 for SU; group 2-€531,06 for rosiglitazone + metformin vs. €540,20 for SU + metformin; group 3-€749,44 for rosiglitazone + SU vs. To estimate incremental drug costs and savings resulting from hypoglycemia risk reduction produced by insulin Glargine compared to NPH insulin from payers perspective in Poland. METHODS: Epidemiological data and expert panel were used to evaluate the number of patients eligible for insulin Glargine treatment in Poland. Logistic model of switching rate from NPH insulin to insuline Glargine was developed for 3 years time horizon for diabetes patients according to NICE guidelines. Net drug costs reflect incremental acquisition costs per i.u. as well as difference between mean daily doses of insulin Glargine and NPH. Savings resulting from hypoglycemia risk reduction were estimated based on literature review and unit cost of hypoglycemic event treatment (payers' perspective; event associated with hospitalization or ER visit). RESULTS: Number of patients eligible for insuline Glargine treatment was estimated at 64 608 patients accounting for 5.48% of all diabetic patients in Poland. Mean annual drug costs were estimated at 24.5 mln EUR (PPP value) while savings resulting from hypoglycemia risk reduction at 4 mln EUR. Subgroup showed for patients with annual hypoglycemia risk reduction associated with insulin Glargine 68.4% drug acquisition expenditures, which are balanced by hypoglycemia treatment savings. CONCLUSIONS: Insulin Glargine treatment was found to be budgetary neutral from payers' perspective for patients with very high risk of hypoglycemia in Poland. Institute for Medical Informatics and Biostatistics (IMIB), Basel, BS, Switzerland; 2 University of Bielefeld, Bielefeld, Germany; 3 Institut für Biometrie, Hannover, Germany OBJECTIVES: It is extremely difficult to assess the prevalence, the total costs of Diabetes mellitus and the impact of self measurement of blood glucose (SMBG) for the German health care system. The last sound assessment of the total costs is based on the CODE-2 study, although this study reflects the situation in 1998. METHODS: In this analysis we assessed the total costs of diabetes mellitus type-2 and self measurement of blood glucose (SMBG) for the German health care system in the year 2004, based on the analysis of a retrospective, multicenter trial carried out recently, dealing with the impact of SMBG on long term patient outcomes. Our assessment is based on costs for 18 diabetes related complications (including surgical interventions), follow-up-costs for these complications, costs for outpatient physician services, cost of antidiabetic and additional pharmaceutical treatment and costs for strips and lancets for patients performing SMBG. RESULTS: Overall, yearly costs for the treatment of diabetes mellitus type-2 and its complications amounts to €3489 per patient. This equals to 4.6% to 8.2% of the German health care expenditure, in function of the estimated prevalence of the disease in Germany. The cost difference between the cohort with and without SMBG was not essential (€276 higher costs in the cohort with SMBG). This cost difference should be connected with a reduction of mortality from 4.6 to 2.7% and a reduction of non-fatal endpoints from 10.4 to 7.2% for the Non-SMBG and SMBG group respectively reported in the underlaying study. CONCLUSIONS: From a public health standpoint, prevention of diabetes mellitus or at minimum prevention of its complications by optimizing glucose metabolism should be given highest priority in times of limited resources for health care. SMBG may be a valuable tool to achieve this target.
PDB13 THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS
To estimate incremental drug costs and savings resulting from hypoglycemia risk reduction produced by insulin Glargine compared to NPH insulin from payers perspective in Poland. METHODS: Epidemiological data and expert panel were used to evaluate the number of patients eligible for insulin Glargine treatment in Poland. Logistic model of switching rate from NPH insulin to insuline Glargine was developed for 3 years time horizon for diabetes patients according to NICE guidelines. Net drug costs reflect incremental acquisition costs per i.u. as well as difference between mean daily doses of insulin Glargine and NPH. Savings resulting from hypoglycemia risk reduction were estimated based on literature review and unit cost of hypoglycemic event treatment (payers' perspective; event associated with hospitalization or ER visit). RESULTS: Number of patients eligible for insuline Glargine treatment was estimated at 64 608 patients accounting for 5.48% of all diabetic patients in Poland. Mean annual drug costs were estimated at 24.5 mln EUR (PPP value) while savings resulting from hypoglycemia risk reduction at 4 mln EUR. Subgroup showed for patients with annual hypoglycemia risk reduction associated with insulin Glargine 68.4% drug acquisition expenditures, which are balanced by hypoglycemia treatment savings. CONCLUSIONS: Insulin Glargine treatment was found to be budgetary neutral from payers' perspective for patients with very high risk of hypoglycemia in Poland. Institut für Biometrie, Hannover, Germany OBJECTIVES: It is extremely difficult to assess the prevalence, the total costs of Diabetes mellitus and the impact of self measurement of blood glucose (SMBG) for the German health care system. The last sound assessment of the total costs is based on the CODE-2 study, although this study reflects the situation in 1998. METHODS: In this analysis we assessed the total costs of diabetes mellitus type-2 and self measurement of blood glucose (SMBG) for the German health care system in the year 2004, based on the analysis of a retrospective, multicenter trial carried out recently, dealing with the impact of SMBG on long term patient outcomes. Our assessment is based on costs for 18 diabetes related complications (including surgical interventions), follow-up-costs for these complications, costs for outpatient physician services, cost of antidiabetic and additional pharmaceutical treatment and costs for strips and lancets for patients performing SMBG. RESULTS: Overall, yearly costs for the treatment of diabetes mellitus type-2 and its complications amounts to €3489 per patient. This equals to 4.6% to 8.2% of the German health care expenditure, in function of the estimated prevalence of the disease in Germany. The cost difference between the cohort with and without SMBG was not essential (€276 higher costs in the cohort with SMBG). This cost difference should be connected with a reduction of mortality from 4.6 to 2.7% and a reduction of non-fatal endpoints from 10.4 to 7.2% for the Non-SMBG and SMBG group respectively reported in the underlaying study. CONCLUSIONS: From a public health standpoint, prevention of diabetes mellitus or at minimum prevention of its complications by optimizing glucose metabolism should be given highest priority in times of limited resources for health care. SMBG may be a valuable tool to achieve this target. Joanneum Research, Graz, Styria, Austria; 2 Medical University Graz, Graz, Styria, Austria OBJECTIVE: The diabetic foot is a complex late complication, it is difficult to treat and has severe impact on quality of life and causes an enormous financial burden for society. Aim of this study was to evaluate structured chiropodist care (CC) with regard to healing rates and costs provided by intensively instructed professionals. METHODS: One year follow-up-data of a randomized and controlled trial (RCT) performed in the province of Styria, Austria showed significantly reduced reulceration rates under chiropodist care. Patients in the intervention group received chiropodist care in average 11 times per year and were reimbursed for the costs (€29 per visit). Based on a published paper Austrian specific cost data of 2001 were used to build a Markov Model to evaluate 10 years outcome. A MonteCarlo-Simulation (n = 10.000) was performed for patients with chiropodist care (intervention) and no chiropodist care (control). RESULTS: Mean follow-up-duration for 91 patients of the RCT was 386 days with a reulceration rate of 36% in the intervention group (n = 47) and 55% in the control group (p = 0.05). The model calculation over 10 years showed treatment costs per patient of €12,094 (SD 13,379) in the intervention and €18,538 (SD 16,120) in the control group. Costs for the general treatment of diabetes were not taken into account. The amputation rate under intervention declined to 40% versus 67% in the control group. Taking the mean life expectancy into account (6.1 vs. 5.1 ys.) average costs per patient-year were 1.985 € in the intervention group versus €3.654 in the control group.
PDB14 COST OF DIABETES MELLITUS

PDB15 A MODEL BASED ANALYSIS OF COSTS AND EFFECTIVENESS OF CHIROPODIST CARE IN DIABETEC PATIENTS
CON-CLUSION:
The model based analysis demonstrated the benefit of CC over a 10 year period in terms of reduced amputation rates and lower costs per patient and year. 
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